Clinical Trials
6 trialsNCT06770296 2025-01-13
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Recruiting
NCT04367090 2023-09-18
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05252546 2022-12-23
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02500199 2021-02-01
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Hengrui Therapeutics, Inc.
Phase 1 Unknown
NCT01937689 2018-07-09
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02378389 2015-03-04
Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown